{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:15Z","timestamp":1791358035724,"version":"4.3.1"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,11,22]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation\u00b1magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity.<\/jats:p>","DOI":"10.1136\/jitc-2020-001675","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T10:53:22Z","timestamp":1613386402000},"page":"e001675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4768-3921","authenticated-orcid":false,"given":"Samuel","family":"Rosner","sequence":"first","affiliation":[{"name":"Department of Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Otolaryngology, Johns Hopkins Hospital, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q","family":"Sun","sequence":"additional","affiliation":[{"name":"Otolaryngology, Johns Hopkins Hospital, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafi","family":"Aygun","sequence":"additional","affiliation":[{"name":"Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan D","family":"Schollenberger","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2976-0911","authenticated-orcid":false,"given":"Evan","family":"Lipson","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"},{"name":"The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA"},{"name":"Beaumont Hospital Dublin, The Royal College of Surgeons Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2025100312423054000_8.2.e001675.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100312423054000_8.2.e001675.2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100312423054000_8.2.e001675.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100312423054000_8.2.e001675.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100312423054000_8.2.e001675.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100312423054000_8.2.e001675.6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0114-4"},{"key":"2025100312423054000_8.2.e001675.7","first-page":"1","article-title":"A case of pembrolizumab induced autoimmune sensorineural hearing loss","volume":"8","author":"Hobelmann","year":"2019","journal-title":"J Otol Rhinol"},{"key":"2025100312423054000_8.2.e001675.8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.05.022","article-title":"Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series","volume":"117","author":"Lemasson","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100312423054000_8.2.e001675.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.4359"},{"key":"2025100312423054000_8.2.e001675.10","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000066"},{"key":"2025100312423054000_8.2.e001675.11","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.jtho.2018.04.026","article-title":"Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer","volume":"13","author":"Tamura","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100312423054000_8.2.e001675.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rcr2.545","article-title":"Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer","volume":"8","author":"Kurono","year":"2020","journal-title":"Respirol Case Rep"},{"key":"2025100312423054000_8.2.e001675.13","unstructured":"National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. 5th ed, 2017. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf [Accessed 21 Aug 2018]."},{"key":"2025100312423054000_8.2.e001675.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100312423054000_8.2.e001675.15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of Anti-Programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100312423054000_8.2.e001675.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.016"},{"key":"2025100312423054000_8.2.e001675.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00066-5"},{"key":"2025100312423054000_8.2.e001675.18","first-page":"CD003869","article-title":"Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases","volume":"1","author":"Tsao","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100312423054000_8.2.e001675.19","article-title":"Investigation of the ototoxic effect of pembrolizumab using a rat model","volume":"11","author":"Kuzucu","year":"2019","journal-title":"Cureus"},{"key":"2025100312423054000_8.2.e001675.20","doi-asserted-by":"publisher","DOI":"10.1177\/0194599812448356"},{"key":"2025100312423054000_8.2.e001675.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00912.x"},{"key":"2025100312423054000_8.2.e001675.22","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199906000-00020"},{"key":"2025100312423054000_8.2.e001675.23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/014556131109000506","article-title":"The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss","volume":"90","author":"Singh Chauhan","year":"2011","journal-title":"Ear Nose Throat J"},{"key":"2025100312423054000_8.2.e001675.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2006.09.015"},{"key":"2025100312423054000_8.2.e001675.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.8822"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:42:40Z","timestamp":1759520560000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/jitc-2020-001675"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001675","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}